Downgrades by analysts, such as the one from BTIG for Gracell Biotechnologies, typically lead to a negative short-term reaction in the stock market as they suggest a less favorable outlook for the company's stock. Investors often use analyst ratings as a guide for their investment decisions, and a downgrade can result in decreased investor confidence and selling pressure.